Search
forLearn
5 / 801 resultslearn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
learn Anasensyl
learn ascorbic acid
learn enoxolone
Research
5 / 344 resultsresearch Symmetrical drug‐related intertriginous and flexural exanthema like eruption associated with COVID‐19 vaccination
A skin rash after the AstraZeneca COVID-19 vaccine was treated successfully with medication.
research Medication-induced hair loss: An update
COVID-19 vaccines have been linked to an increase in hair loss conditions.
research How coronavirus disease 2019 vaccination affect the level of vitamin D in serum and hair?
COVID-19 vaccination may lower vitamin D levels and cause hair loss.
research Prevalence of hair loss in Egyptian people after covid -19 vaccination.
Hair loss is not clearly linked to COVID-19 vaccination in Egyptians.
research Recurrence of cutaneous T‐cell lymphoma post viral vector COVID‐19 vaccination
COVID-19 vaccination may trigger recurrence of cutaneous T-cell lymphoma in some patients.
Community Join
5 / 1000+ resultscommunity Why don't the Nizoral manufacturers promote their product for MPB?
Ketoconazole is somewhat effective for male pattern baldness (MPB), but the manufacturer promotes it for dandruff instead, possibly because the dandruff market is larger and to avoid confusion among dandruff sufferers without hair loss.
community We already know how to permanently fix hair loss. The science is done. The only thing missing is the funding to run one experiment.
A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
community ASATONA AG and "Asatex"
The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.
community EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.